Pre-made Diridavumab benchmark antibody ( Whole mAb, anti-Influenza A HA2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-147
Pre-Made Diridavumab biosimilar, Whole Mab: Anti-Influenza A HA2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Diridavumab (CR6261) (INN) is a monoclonal antibody designed for the treatment of influenza A.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Diridavumab biosimilar, Whole Mab: Anti-Influenza A HA2 therapeutic antibody|
|Target||Influenza A HA2|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||3gbn:HL/3gbm:HL:IM/5c0s:HL|
|99% SI Structure||None|
|95-98% SI Structure||4evn:AB:CD:IJ:OP:KL:EF:GH:MN|
|Companies||National Institute of Allergy and Infectious Diseases;Crucell|
|Conditions Active||Influenza A virus (H1N1) infections|